Alvotech Enters Next Stage For Entyvio Rival

Confirmatory Patient Study Begins For AVT16, One Of Two Proposed Vedolizumab Biosimilars

 
• By Dave Wallace

As it announced the start of trials for its AVT16 proposed rival to Takeda’s Entyvio, Alvotech reiterated that it is one of just two publicly-disclosed biosimilar developers targeting vedolizumab.

Player 01 vs Player 02
Alvotech sees itself as one of only two players on vedolizumab • Source: Shutterstock

More from Biosimilars

More from Products